Seven Fleet Capital Management LP Makes New Investment in Dianthus Therapeutics, Inc. $DNTH

Seven Fleet Capital Management LP bought a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 64,723 shares of the company’s stock, valued at approximately $6,309,198,000. Dianthus Therapeutics accounts for 1.0% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 22nd biggest holding. Seven Fleet Capital Management LP owned approximately 0.12% of Dianthus Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DNTH. Artia Global Partners LP purchased a new position in Dianthus Therapeutics during the second quarter valued at $15,888,000. Bank of America Corp DE bought a new position in shares of Dianthus Therapeutics in the 2nd quarter worth about $25,036,000. Jupiter Topco LLC purchased a new position in Dianthus Therapeutics during the 2nd quarter valued at about $1,511,000. ABS Investment Management LLC bought a new stake in Dianthus Therapeutics during the second quarter worth about $194,960,000. Finally, EFG International AG purchased a new stake in Dianthus Therapeutics in the second quarter worth about $49,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Trading Down 1.2%

NASDAQ:DNTH opened at $110.76 on Thursday. Dianthus Therapeutics, Inc. has a 12 month low of $22.81 and a 12 month high of $117.88. The company has a market cap of $6.05 billion, a PE ratio of -26.69 and a beta of 1.22. The company has a 50 day simple moving average of $102.55 and a two-hundred day simple moving average of $86.52.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. Research analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on DNTH shares. Truist Financial boosted their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Finally, HC Wainwright upped their price target on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $124.27.

Insider Buying and Selling

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $362,480. This represents a 86.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marino Garcia sold 166,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the transaction, the chief executive officer directly owned 65,292 shares in the company, valued at $7,058,718.12. The trade was a 71.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 287,084 shares of company stock valued at $29,615,923 in the last 90 days. Insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.